Critical Comparison: Opko Health (OPK) vs. Akcea Therapeutics (AKCA)
Opko Health (NASDAQ: OPK) and Akcea Therapeutics (NASDAQ:AKCA) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Earnings & Valuation
This table compares Opko Health and Akcea Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Opko Health||$1.22 billion||2.25||-$25.08 million||($0.19)||-25.89|
|Akcea Therapeutics||N/A||N/A||-$83.21 million||($3.94)||-4.91|
Opko Health has higher revenue and earnings than Akcea Therapeutics. Opko Health is trading at a lower price-to-earnings ratio than Akcea Therapeutics, indicating that it is currently the more affordable of the two stocks.
This table compares Opko Health and Akcea Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider & Institutional Ownership
22.9% of Opko Health shares are owned by institutional investors. Comparatively, 26.0% of Akcea Therapeutics shares are owned by institutional investors. 40.2% of Opko Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This is a breakdown of current ratings and recommmendations for Opko Health and Akcea Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Opko Health presently has a consensus price target of $14.81, suggesting a potential upside of 201.07%. Akcea Therapeutics has a consensus price target of $24.00, suggesting a potential upside of 24.16%. Given Opko Health’s higher probable upside, equities analysts clearly believe Opko Health is more favorable than Akcea Therapeutics.
About Opko Health
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women’s Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.
About Akcea Therapeutics
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company’s drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company’s volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company’s clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with Analyst Ratings Network's FREE daily email newsletter.